CFRX Key Statistics, Chart & Performance
The current stock price of CFRX is 0.2318 USD. In the past month the price decreased by -52.79%. In the past year, price decreased by -97.99%.
CFRX Technical Analysis
CFRX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CFRX. Both the profitability and financial health of CFRX have multiple concerns.
CFRX Financial Highlights
Over the last trailing twelve months CFRX reported a non-GAAP Earnings per Share(EPS) of -37.17. The EPS increased by 61.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -186.23% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CFRX Forecast & Estimates
7 analysts have analysed CFRX and the average price target is 5.1 USD. This implies a price increase of 2100.17% is expected in the next year compared to the current price of 0.2318.
CFRX Ownership
About CFRX
Company Profile
ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. The company is headquartered in Yonkers, New York and currently employs 23 full-time employees. The company went IPO on 2014-07-29. The firm is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase (CF-301), is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its CF-301 is being studied in an ongoing Phase Ib/II study in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumanni, and has demonstrated potent in vivo activity against these pathogens.
Company Info
CONTRAFECT CORP
28 Wells Avenue, 3rd Floor
Yonkers NEW YORK 10701 US
CEO: Roger J. Pomerantz
Employees: 23
Phone: 19142072300.0
CONTRAFECT CORP / CFRX FAQ
What does CFRX do?
ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. The company is headquartered in Yonkers, New York and currently employs 23 full-time employees. The company went IPO on 2014-07-29. The firm is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase (CF-301), is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its CF-301 is being studied in an ongoing Phase Ib/II study in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumanni, and has demonstrated potent in vivo activity against these pathogens.
Can you provide the latest stock price for CONTRAFECT CORP?
The current stock price of CFRX is 0.2318 USD. The price increased by 2.84% in the last trading session.
What is the dividend status of CONTRAFECT CORP?
CFRX does not pay a dividend.
How is the ChartMill rating for CONTRAFECT CORP?
CFRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of CONTRAFECT CORP (CFRX)?
CONTRAFECT CORP (CFRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-37.17).
Would investing in CONTRAFECT CORP be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CFRX.
How many employees does CONTRAFECT CORP have?
CONTRAFECT CORP (CFRX) currently has 23 employees.